Dogecoin Cash, Inc. Subsidiary PrestoDoctor Now Accepts Cryptocurrency Payments, Including Dogecoin
MWN-AI** Summary
Dogecoin Cash, Inc. ($CBDS), a prominent player in the blockchain sector, has announced that its subsidiary, PrestoDoctor, has integrated cryptocurrency payments, including its signature coin, Dogecoin (DOGE). This strategic move aims to enhance the healthcare experience for patients seeking medical cannabis evaluations through its telemedicine platform.
David Tobias, CEO of Dogecoin Cash, emphasized the convenience that accepting cryptocurrencies will offer patients. By aligning with the growing preferences for digital assets, PrestoDoctor positions itself as a forward-thinking platform. In addition to Dogecoin, the company will accept a diverse array of cryptocurrencies, including Bitcoin (BTC), Ethereum (ETH), and Litecoin (LTC), among others. This variety aims to make medical cannabis evaluations more accessible to a tech-savvy audience familiar with blockchain-based finance.
Kyle Powers, CEO of PrestoDoctor, highlighted that the integration of crypto payments not only enhances convenience but also provides added privacy for patients, thereby addressing evolving expectations in healthcare and digital finance. Traditional payment methods will remain available, ensuring a comprehensive range of choices for patients.
Dogecoin Cash, Inc. is committed to advancing blockchain technology across sectors like healthcare, finance, and consumer services. Through PrestoDoctor, the company continues to provide secure, HIPAA-compliant telemedicine services, connecting patients with licensed professionals discreetly and conveniently.
As the landscape of healthcare and finance evolves, Dogecoin Cash's emphasis on decentralized technologies reflects a growing trend towards integrating cryptocurrency into everyday transactions, a significant pivot in both the medical and financial sectors. For more detailed information, the company directs interested parties to its official website and supporting platforms.
MWN-AI** Analysis
As of September 2025, Dogecoin Cash, Inc. ($CBDS) is making significant strides in the evolving landscape of both cryptocurrency and healthcare by allowing its subsidiary, PrestoDoctor, to accept a variety of cryptocurrencies, with a notable emphasis on Dogecoin (DOGE). This strategic move not only positions DOGE as a frontrunner in the digital asset space but also enhances PrestoDoctor’s appeal to a tech-savvy, younger demographic interested in medical cannabis.
This payment integration reflects a broader trend in which companies seek to adapt to consumer preferences for flexible payment solutions. For investors, this development can be interpreted as a potent signal of market innovation and relevance, signaling potential growth of demand for services like those offered by PrestoDoctor. As evidenced by the recent adoption of cryptocurrency in diverse sectors, Dogecoin Cash, Inc. is effectively positioning itself to capture market share in both the telehealth and cryptocurrency realms.
Additionally, the acceptance of a wide array of cryptocurrencies—ranging from Bitcoin (BTC) to Solana (SOL)—suggests a calculated approach to mitigating risks associated with reliance on a single digital asset. This diverse portfolio could result in increased transaction volumes and stability in cash flows, further boosting investor confidence.
However, potential investors should remain cognizant of the inherent volatility in the cryptocurrency market, particularly with altcoins like DOGE. It’s also essential to monitor regulatory developments in the healthcare and financial technology sectors as they may impact operational viability.
In conclusion, Dogecoin Cash, Inc.'s latest initiative reflects a convergence of healthcare and cryptocurrency, presenting an intriguing investment opportunity. Investors should consider both the growth potential and the risks associated with the fluctuating landscape of digital payments and regulatory scrutiny in telemedicine. Regularly reviewing the company's performance in relation to these dynamics will be crucial for informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MESQUITE, NV, Sept. 10, 2025 (GLOBE NEWSWIRE) --
September 10, 2025 – Mesquite, NV – Dogecoin Cash, Inc. (), a publicly traded leader in blockchain innovation,announced that its wholly owned subsidiary, PrestoDoctor , a leading telemedicine platform for medical cannabis evaluations, has begun accepting cryptocurrency payments for its services. This includes a wide range of digital assets, with an emphasis on the Company’s namesake coin, Dogecoin (DOGE) . This move is part of Dogecoin Cash, Inc.’s broader strategy to embrace decentralized technologies and offer patients a more flexible, forward-looking healthcare experience. “As digital assets continue to gain broader use, we are pleased to offer our patients the convenience of paying with cryptocurrency,” said David Tobias, CEO of Dogecoin Cash, Inc. “By accepting Dogecoin and other leading cryptocurrencies, PrestoDoctor is taking another step toward aligning with the evolving preferences of our patient community.”
The accepted cryptocurrencies now include :
- Bitcoin (BTC)
- Ethereum (ETH)
- USD Coin (USDC)
- Tron (TRX)
- Tether (USDT)
- BNB (Binance Coin)
- Dogecoin (DOGE)
- Litecoin (LTC)
- Monero (XMR)
- Polygon (MATIC)
- Bitcoin Cash (BCH)
- Shiba Inu (SHIB)
- Solana (SOL)
- DAI
With the integration of these cryptocurrencies, PrestoDoctor aims to make medical cannabis evaluations more accessible to a broader and more tech-savvy patient base, particularly those already engaged with blockchain-based finance.
Traditional payment methods such as credit cards and debit cards will continue to be supported, ensuring all patients can choose the payment method that best suits their needs.
“The integration of crypto payments isn’t just about convenience; it’s about staying ahead of the curve and offering enhanced privacy for our patients,” added Kyle Powers, CEO. “We believe this positions PrestoDoctor to better adapt to the changing landscape of both healthcare and digital finance.”
About Dogecoin Cash, Inc.
Dogecoin Cash, Inc. (OTCQB: DOGP) is a publicly traded company focused on the advancement of blockchain technology and its practical applications in healthcare, finance, and consumer services. Through its subsidiary PrestoDoctor, the Company provides telemedicine solutions for patients seeking medical cannabis evaluations across multiple U.S. states.
For more information about Dogecoin Cash, Inc. visit www.dogecoincash.com
About PrestoDoctor
PrestoDoctor is a leader in online medical cannabis evaluations, offering secure, HIPAA-compliant telemedicine services that connect patients with licensed physicians in a convenient and discreet manner.
For more information, please visit https://prestodoctor.com/resources/crypto
Forward Looking Statement
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as may be disclosed in the Company's filings. In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors, including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release, and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release. Such forward-looking statements are risks that are detailed on the Company's website and filings. This press release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those projected. For a detailed discussion of these risks and uncertainties, please refer to Dogecoin Cash, Inc.'s filings with the SEC.
FAQ**
How does the acceptance of cryptocurrency payments by PrestoDoctor enhance the patient experience for medical cannabis evaluations under the publicly traded entity DOGP?
What specific strategies is DOGP implementing to ensure the security and privacy of cryptocurrency transactions made through PrestoDoctor?
What potential growth opportunities does DOGP foresee in the telemedicine sector as more patients opt for cryptocurrency payments?
How does DOGP plan to distinguish itself from competitors in the telemedicine and blockchain space as it embraces decentralized technologies?
**MWN-AI FAQ is based on asking OpenAI questions about Cannabis Sativa Inc (OTC: CBDS).
NASDAQ: CBDS
CBDS Trading
-6.64% G/L:
$0.02757 Last:
783,096 Volume:
$0.0294 Open:
